<DOC>
	<DOCNO>NCT00405652</DOCNO>
	<brief_summary>Treatment immunosuppressive drug mycophenolate mofetil ( MMF ) may result gastrointestinal ( GI ) complication patient . This study assess switch MMF enteric-coated mycophenolate sodium ( EC-MPS ) result improve GI and/or health-related quality life liver transplant recipient</brief_summary>
	<brief_title>Measurement Gastrointestinal ( GI ) Health-related Quality Life ( HRQL ) Outcomes Liver Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Received liver transplant least 3 month prior study enrollment . Receiving immunosuppressive regimen include calcineurin mTOR inhibitor , MMF time study enrolment . The patient must stable current immunosuppressive regimen . The MMF dose must stable least 1 month prior enrollment . Steroid use accord local practice . Patients enrol study expect treatment continue dose study end ( 68 week enrollment ) . Patients medical condition necessitates MPAtreatment probably next 6 8 week ( time study duration ) . Patients least mild overall Gastrointestinal ( G ) I complication assess GI complication Case Report Form ( CRF ) . Eligible willing convert Myfortic . At lease 18 year age . Willing provide write informed consent . Able meet study requirement include complete questionnaire complete 2 study visit . Patients receive drug may cause GI symptom bisphosphonates , mineral , vitamin , antibiotic proton pump inhibitor ( PPIs ) stable dose substance least 1 month prior enrollment . Patients receive drug enrol study , expect treatment continue dose study end ( 68 week enrollment ) . Females capable become pregnant must negative pregnancy test within 7 day prior baseline . Pregnancy test repeat every 4 week . Females require practice approve method birth control duration study period 6 week follow discontinuation study medication , even history infertility . Exclusion criterion : If applicable , GI symptoms assume know cause MPA therapy ( e.g . oral bisphosphonates induce , infection diarrhea ) . Acute rejection &lt; 1 week prior study enrollment Patients Alanine aminotransferase ( ALT ) , Aspartate aminotransferase ( AST ) or/ bilirubin value &gt; =3 x Upper limit normal ( ULN ) ( value available last routine assessment within 3 month acceptable ) . Patients serum creatinine value &gt; =265 umol/L ( value available last routine assessment within 3 month acceptable ) . Patients hemoglobin value &lt; 7g/dL and/or absolute platelet count &lt; 50 x 10^9/L /or absolute leukocytes count &lt; 2.0 x10^9/L ( value available last routine assessment within 3 month acceptable . ) Woman childbearing potential planning become pregnant pregnant and/or lactate unwilling use effective mean contraception . Presence psychiatric illness ( i.e. , schizophrenia , major depression ) , opinion site investigator , could interfere study requirement . Undergoing acute medical intervention hospitalization . Presence medical condition relate GI event time visit , require immediate medical intervention . Any medical condition , opinion site investigator base recall chart review , interfere complete study , include limited , visual problem cognitive impairment . Receiving investigational drug receive investigational drug within 30 day prior study enrollment . Patients hypersensitivity mycophenolate sodium , mycophenolic acid , mycophenolic mofetil component formulation ( e.g . lactose ; see also SmPCs ) Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>Liver transplantation , mycophenolate , GI problem , Quality Life</keyword>
</DOC>